Ironwood Pharmaceuticals Inc. Insider Trading

IRWD

Last 12 months

Insiders sold $22.6M and bought nothing on the open market.

4% of the selling was scheduled in advance under 10b5-1 plans. Director Alexander J Denner sold $20.5M on Mar 17, 27% of their stake, outside a plan. The last open-market buy by an executive or director was in Mar 2024.

Net open-market

−$22.6M

0 buys · 11 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

Mar 2024

Mar 6, 2024

Get an email when IRWD's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 7	Ronald Silver Pfo & Pao	Sold10b5-1 plan	127,890	$4.52	578K	29%	Form 4
Jun 16	Julie McHugh Director	Sold10b5-1 plan	21,571	$3.73	80K	7.9%	Form 4
Mar 17	Alexander J Denner Director	SoldNo plan 2 parts	6,730,800	$3.05 average	$20.5M	27%	Form 4
Feb 23 – 24	Gregory S. Martini Chief Financial Officer	SoldNo plan 2 parts	21,944	$3.73 average	82K	12%	Form 4
Feb 23 – 24	Minardo John Chief Legal Officer	SoldNo plan 2 parts	36,492	$3.73 average	136K	9.1%	Form 4
Feb 23 – 24	Michael Shetzline SVP, CMO, Head-Res&Drug	SoldNo plan 2 parts	32,582	$3.73 average	122K	3.0%	Form 4
Feb 23 – 24	Tammi L Gaskins Chief Commercial Officer	SoldNo plan 2 parts	21,526	$3.73 average	80K	9.1%	Form 4
Feb 23 – 24	Thomas A McCourt Chief Executive Officer	SoldNo plan 2 parts	198,283	$3.73 average	740K	12%	Form 4
Feb 23 – 24	Ronald Silver Principal Accounting Officer	SoldNo plan 2 parts	24,173	$3.73 average	90K	8.7%	Form 4
Jan 5	Ronald Silver Principal Accounting Officer	Sold10b5-1 plan	35,416	$4.60	163K	11%	Form 4
Nov 17, 2025	Tammi L Gaskins Chief Commercial Officer	SoldNo plan	6,016	$3.32	20K	2.5%	Form 4
Aug 11, 2025	Tammi L Gaskins Chief Commercial Officer	SoldNo plan	1,316	$0.84	1K	0.5%	Form 4
Aug 11, 2025	Minardo John Chief Legal Officer	SoldNo plan	7,754	$0.84	7K	1.9%	Form 4
Aug 11, 2025	Ronald Silver Principal Accounting Officer	SoldNo plan	2,846	$0.84	2K	1.0%	Form 4
Aug 11, 2025	Gregory S. Martini Chief Financial Officer	SoldNo plan	1,265	$0.84	1K	0.7%	Form 4
May 16, 2025	Thomas A McCourt Chief Executive Officer	SoldNo plan	13,353	$0.58	8K	0.8%	Form 4
May 16, 2025	Tammi L Gaskins Chief Commercial Officer	SoldNo plan	2,563	$0.58	1K	1.0%	Form 4
Feb 10, 2025	Thomas A McCourt Chief Executive Officer	SoldNo plan	139,064	$1.76	245K	11%	Form 4
Feb 10, 2025	Ronald Silver Principal Accounting Officer	SoldNo plan	12,048	$1.76	21K	4.1%	Form 4
Feb 10, 2025	Michael Shetzline SVP, CMO, Head-Res&Drug	SoldNo plan	41,269	$1.76	73K	6.9%	Form 4
Feb 10, 2025	Minardo John Chief Legal Officer	SoldNo plan	38,938	$1.76	69K	8.7%	Form 4
Feb 10, 2025	Gregory S. Martini Chief Financial Officer	SoldNo plan	12,052	$1.76	21K	6.2%	Form 4
Nov 18, 2024	Andrew Davis SVP, Chief Business Officer	SoldNo plan	5,360	$4.08	22K	1.8%	Form 4
Nov 18, 2024	Sravan Kumar Emany SVP, COO and CFO	SoldNo plan	11,001	$4.08	45K	3.4%	Form 4

Jul 710b5-1 plan
Ronald Silver
Pfo & Pao · sold 127,890 at $4.52
578K
29% of stake
Jun 1610b5-1 plan
Julie McHugh
Director · sold 21,571 at $3.73
80K
7.9% of stake
Mar 17No plan
Alexander J Denner
Director · sold 6,730,800 at avg $3.05
$20.5M
27% of stake
Feb 23 – 24No plan
Gregory S. Martini
Chief Financial Officer · sold 21,944 at avg $3.73
82K
12% of stake
Feb 23 – 24No plan
Minardo John
Chief Legal Officer · sold 36,492 at avg $3.73
136K
9.1% of stake
Feb 23 – 24No plan
Michael Shetzline
SVP, CMO, Head-Res&Drug · sold 32,582 at avg $3.73
122K
3.0% of stake
Feb 23 – 24No plan
Tammi L Gaskins
Chief Commercial Officer · sold 21,526 at avg $3.73
80K
9.1% of stake
Feb 23 – 24No plan
Thomas A McCourt
Chief Executive Officer · sold 198,283 at avg $3.73
740K
12% of stake
Feb 23 – 24No plan
Ronald Silver
Principal Accounting Officer · sold 24,173 at avg $3.73
90K
8.7% of stake
Jan 510b5-1 plan
Ronald Silver
Principal Accounting Officer · sold 35,416 at $4.60
163K
11% of stake
Nov 17, 2025No plan
Tammi L Gaskins
Chief Commercial Officer · sold 6,016 at $3.32
20K
2.5% of stake
Aug 11, 2025No plan
Tammi L Gaskins
Chief Commercial Officer · sold 1,316 at $0.84
1K
0.5% of stake
Aug 11, 2025No plan
Minardo John
Chief Legal Officer · sold 7,754 at $0.84
7K
1.9% of stake
Aug 11, 2025No plan
Ronald Silver
Principal Accounting Officer · sold 2,846 at $0.84
2K
1.0% of stake
Aug 11, 2025No plan
Gregory S. Martini
Chief Financial Officer · sold 1,265 at $0.84
1K
0.7% of stake
May 16, 2025No plan
Thomas A McCourt
Chief Executive Officer · sold 13,353 at $0.58
8K
0.8% of stake
May 16, 2025No plan
Tammi L Gaskins
Chief Commercial Officer · sold 2,563 at $0.58
1K
1.0% of stake
Feb 10, 2025No plan
Thomas A McCourt
Chief Executive Officer · sold 139,064 at $1.76
245K
11% of stake
Feb 10, 2025No plan
Ronald Silver
Principal Accounting Officer · sold 12,048 at $1.76
21K
4.1% of stake
Feb 10, 2025No plan
Michael Shetzline
SVP, CMO, Head-Res&Drug · sold 41,269 at $1.76
73K
6.9% of stake
Feb 10, 2025No plan
Minardo John
Chief Legal Officer · sold 38,938 at $1.76
69K
8.7% of stake
Feb 10, 2025No plan
Gregory S. Martini
Chief Financial Officer · sold 12,052 at $1.76
21K
6.2% of stake
Nov 18, 2024No plan
Andrew Davis
SVP, Chief Business Officer · sold 5,360 at $4.08
22K
1.8% of stake
Nov 18, 2024No plan
Sravan Kumar Emany
SVP, COO and CFO · sold 11,001 at $4.08
45K
3.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch IRWD, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with IRWD

CompareIntrinsic value

MNKDMannKind Corporation

$3.50+0.00%30

ESPREsperion Therapeutics Inc.

No recent price50

INVAInnoviva Inc.

$21.22-0.42%56

XERSXeris Biopharma Holdings, Inc.

$10.71-0.37%30

ZLABZai Lab Ltd

$22.07-1.30%40

ARDXArdelyx Inc.

$3.03-2.26%40

LQDALiquidia Corporation

$45.05+0.13%72

ORGOOrganogenesis Holdings Inc.

$0.77-6.23%50

Held by ETFs

IRWD is in 35 US ETFs. The largest of them, with IRWD's weight in each:

Spot a number that looks wrong? Check it in IRWD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IRWD

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.